Growth Opportunities in the Global Digital Therapeutics Market

Growth Opportunities in the Global Digital Therapeutics Market

Preventive Care and Market Access Strategies Spur New Growth Opportunities

RELEASE DATE
21-Sep-2023
REGION
North America
Research Code: PF19-01-00-00-00
SKU: CM_2023_146
AvailableYesPDF Download
$4,950.00
In stock
SKU
CM_2023_146
$4,950.00
DownloadLink
ENQUIRE NOW

Description

This study presents Frost & Sullivan’s overall market and segment-wise revenue forecasts of the global digital therapeutics (DTx) market and highlights key growth opportunities for global DTx market participants.

Patients with long-term chronic conditions increasingly seek safe, evidence-based digital treatments to reduce their medication dosages, reverse triggers of adverse events, and limit healthcare utilization. This is due to the high cost of care associated with these conditions and the need for effective and affordable solutions. Payers and providers seek cost-effective medication alternatives to improve patient engagement, adherence, and convenience while promoting value-based care. The need for disease-reversal and preventive care solutions is also seeing huge demand. Life sciences (LS) companies aim to develop 'around the pill' combination products to enhance patients' treatment experiences. They are also searching for digital biomarkers to assist in drug discovery in the future. LS is partnering with DTx companies to expand their pipelines and develop new treatments for unmet medical needs. In addition, LS is helping DTx companies grow their patient reach globally and achieve their health equity objectives. Collaborations between DTx vendors and medical device companies are also facilitating dosage optimization for personalized therapeutics.

Most digital health technologies have long suffered from being unable to systematically prove their solutions' clinical efficacy via peer-reviewed reports. Thus, they have never secured the unique distinction of being a regulated and "prescription-grade" digital treatment plan that guarantees improved patient outcomes and comprehensive reimbursement at the same time. With the support of rigorous and high-quality decentralized clinical trials, more DTx companies will focus on generating strong clinical, RWE, and HEOR data to prove the safety and effectiveness of their products and drive widespread commercialization.

Additionally, the convergence of biopharma, medical devices, and health technology will play a significant role in shifting toward integrated patient management and holistically supporting the entire patient journey. DTx companies focused on the patient experience must utilize a variety of business models tailored to different customer types, allowing for scalable solutions that enable physicians to recommend their products, patients to use them consistently for a defined period, caregivers to monitor outcomes round the clock, and payers to reimburse the cost of usage.

Collaboration between DTx and LS companies will increase, enabling broader patient reach and increasing scalability alongside risk-sharing agreements. DTx solutions are now considered valid alternatives or adjuncts to traditional pharmacotherapy and are subject to comprehensive regulation. They have been granted prescription status by national or state-level regulatory agencies, such as the FDA, NHS, and CE, based on evidence of improved clinical outcomes for specific patient groups.

The United States is a significant market for growth on a global scale, followed by Europe, where Germany leads the way owing to the highest DTx adoption attractiveness in this region. It is due to higher reimbursement rates and early adoption by payers, providers, and companies in the life sciences and medical device industries.

The disease management application is expected to make up a significant portion of the DTx market revenue worldwide. These solutions enable better patient engagement in chronic care management, lowering healthcare utilization and encouraging self-management of symptoms. This, in turn, incentivizes providers to incorporate these solutions as part of adjunct treatment approaches. Diabetes is expected to have the highest share in revenue within therapy areas and a high CAGR growth rate. This is due to the increasing demand for diabetes management solutions caused by the rising diabetic population worldwide. Additionally, there has been an increase in partnerships between pharma and digital insulin management solutions for connected care. The wellness and behavior management sector will experience revenue growth due to the high demand for mental and cognitive health solutions globally, as well as employers partnering with DTx vendors to provide solutions that enhance employee productivity and wellness. Immersive therapeutics will emerge as an effective treatment approach targeting hard-to-reach and high-risk behavioral health conditions, enhancing patient engagement.

Payers are the primary business users contributing to DTx market revenue. They are expected to reimburse 60% to 66% of the market revenue through different value-based payment plans that patients will be automatically eligible for or subscribed to based on referrals from physicians or formulary decision-makers. Additionally, the role of the providers will become significant as DTx solutions enhance the entire prescriber experience and elevate the current standard of care.

Author: Supriya Lala Kundu

RESEARCH: INFOGRAPHIC

This infographic presents a brief overview of the research, and highlights the key topics discussed in it.
Click image to view it in full size

Table of Contents

Why is it Increasingly Difficult to Grow?

The Strategic Imperative 8™

The Impact of the Top 3 Strategic Imperatives on the Digital Therapeutics Industry

Growth Opportunities Fuel the Growth Pipeline Engine™

Scope of Analysis

Introduction to DTx Solutions

Introduction to DTx Solutions (continued)

The Ten Core Principles All DTx Must Follow

DTx Product Categorization

DTx Mechanisms and Delivery Routes

Application, Therapy Area, and Business Segmentation

Market Segmentation By Application

Market Segmentation By Therapy Area

Segmentation by Geography

Key Competitors

Growth Metrics

Growth Drivers

Growth Restraints

Per Capital Healthcare Spending Analysis

DTx Approval and Diversification Across Therapy Areas

Key Market Trends

Key Market Trends (continued)

Unlocking Commercial Viability Through DCT Model

Regulatory Outlook—United States and Europe

Regulatory Outlook—United States and Europe (continued)

DTx—Regulatory Outlook: APAC

Regulatory Outlook, MENASA, LATAM, and the Caribbean

Global Reimbursement and Market Access Trends

Global Reimbursement and Market Access Trends (continued)

Global Reimbursement and Market Access Trends (continued)

Funding Landscape

Business Model Description

Business Model Description (continued)

Business Model Description (continued)

Summary Analysis of the Top 5 Business Models

Summary Analysis of the Top 5 Business Models (continued)

Summary Analysis of the Top 5 Business Models (continued)

Forecast Assumptions and Limitations

Revenue Forecast

Revenue Forecast by Application

Revenue Forecast Analysis

Revenue Forecast by Region

Revenue Forecast Analysis by Region—North America and Europe

Revenue Forecast Analysis by Region—APAC

Revenue Forecast Analysis by Region—MENASA, LATAM, and the Caribbean

Revenue Forecast by Therapy Area

Revenue Forecast Discussion—Therapy areas

Revenue Share by Business

Revenue Share Analysis by Business

Revenue Share Analysis by Business (continued)

Revenue Share Analysis by Business (continued)

Pricing Trends and Forecast Analysis

Competitive Environment

Revenue Share

Revenue Share Analysis

Revenue Share Analysis (continued)

Key Competitors and Product Offerings

Key Competitors and Product Offerings (continued)

Key Competitors and Product Offerings (continued)

Key Competitors and Product Offerings (continued)

Key Competitors and Product Offerings (continued)

Key Competitors and Product Offerings (continued)

Key Competitors and Product Offerings (continued)

Growth Metrics

Revenue Forecast

Forecast Analysis—Disease management

Use Cases—Adoption in Disease Management

Growth Metrics

Revenue Forecast

Forecast Analysis—Wellness and Behavior Management

Use Cases—Adoption in Wellness and Behavioral Management

Growth Opportunity 1: DTx to Treat Cancer-related Distress, Provide Incidence Prediction, and Elevate QoL

Growth Opportunity 1: DTx to Treat Cancer-related Distress, Provide Incidence Prediction, and Elevate QoL (continued)

Growth Opportunity 2: Drug Adherence and Personalized Coaching Solutions for Chronic Diseases

Growth Opportunity 2: Drug Adherence and Personalized Coaching Solutions for Chronic Diseases (continued)

Growth Opportunity 3: Digital Biomarkers for Predictive and Preventive Care

Growth Opportunity 3: Digital Biomarkers for Predictive and Preventive care (continued)

Growth Opportunity 4: Immersive Therapeutics for Personalized Care

Growth Opportunity 4: Immersive Therapeutics for Personalized Care (continued)

Your Next Steps

Why Frost, Why Now?

List of Exhibits

List of Exhibits (continued)

Legal Disclaimer

This study presents Frost & Sullivan’s overall market and segment-wise revenue forecasts of the global digital therapeutics (DTx) market and highlights key growth opportunities for global DTx market participants. Patients with long-term chronic conditions increasingly seek safe, evidence-based digital treatments to reduce their medication dosages, reverse triggers of adverse events, and limit healthcare utilization. This is due to the high cost of care associated with these conditions and the need for effective and affordable solutions. Payers and providers seek cost-effective medication alternatives to improve patient engagement, adherence, and convenience while promoting value-based care. The need for disease-reversal and preventive care solutions is also seeing huge demand. Life sciences (LS) companies aim to develop 'around the pill' combination products to enhance patients' treatment experiences. They are also searching for digital biomarkers to assist in drug discovery in the future. LS is partnering with DTx companies to expand their pipelines and develop new treatments for unmet medical needs. In addition, LS is helping DTx companies grow their patient reach globally and achieve their health equity objectives. Collaborations between DTx vendors and medical device companies are also facilitating dosage optimization for personalized therapeutics. Most digital health technologies have long suffered from being unable to systematically prove their solutions' clinical efficacy via peer-reviewed reports. Thus, they have never secured the unique distinction of being a regulated and "prescription-grade" digital treatment plan that guarantees improved patient outcomes and comprehensive reimbursement at the same time. With the support of rigorous and high-quality decentralized clinical trials, more DTx companies will focus on generating strong clinical, RWE, and HEOR data to prove the safety and effectiveness of their products and drive widespread commercialization. Additionally, the convergence of biopharma, medical devices, and health technology will play a significant role in shifting toward integrated patient management and holistically supporting the entire patient journey. DTx companies focused on the patient experience must utilize a variety of business models tailored to different customer types, allowing for scalable solutions that enable physicians to recommend their products, patients to use them consistently for a defined period, caregivers to monitor outcomes round the clock, and payers to reimburse the cost of usage. Collaboration between DTx and LS companies will increase, enabling broader patient reach and increasing scalability alongside risk-sharing agreements. DTx solutions are now considered valid alternatives or adjuncts to traditional pharmacotherapy and are subject to comprehensive regulation. They have been granted prescription status by national or state-level regulatory agencies, such as the FDA, NHS, and CE, based on evidence of improved clinical outcomes for specific patient groups. The United States is a significant market for growth on a global scale, followed by Europe, where Germany leads the way owing to the highest DTx adoption attractiveness in this region. It is due to higher reimbursement rates and early adoption by payers, providers, and companies in the life sciences and medical device industries. The disease management application is expected to make up a significant portion of the DTx market revenue worldwide. These solutions enable better patient engagement in chronic care management, lowering healthcare utilization and encouraging self-management of symptoms. This, in turn, incentivizes providers to incorporate these solutions as part of adjunct treatment approaches. Diabetes is expected to have the highest share in revenue within therapy areas and a high CAGR growth rate. This is due to the increasing demand for diabetes management solutions caused by the rising diabetic population worldwide. Additionally, there has been an increase in partnerships between pharma and digital insulin management solutions for connected care. The wellness and behavior management sector will experience revenue growth due to the high demand for mental and cognitive health solutions globally, as well as employers partnering with DTx vendors to provide solutions that enhance employee productivity and wellness. Immersive therapeutics will emerge as an effective treatment approach targeting hard-to-reach and high-risk behavioral health conditions, enhancing patient engagement. Payers are the primary business users contributing to DTx market revenue. They are expected to reimburse 60% to 66% of the market revenue through different value-based payment plans that patients will be automatically eligible for or subscribed to based on referrals from physicians or formulary decision-makers. Additionally, the role of the providers will become significant as DTx solutions enhance the entire prescriber experience and elevate the current standard of care. Author: Supriya Lala Kundu
More Information
Author Supriya Lala Kundu
Industries Chemicals and Materials
No Index No
Is Prebook No
Keyword 1 Digital Therapeutic Applications
Keyword 2 Digital Health Market Analysis
Keyword 3 Personalized Healthcare Solutions
Podcast No
WIP Number PF19-01-00-00-00